Evaxion Biotech A/S - ADR
NASDAQ:EVAX 4:00:00 PM EDT
| Market Cap (Intraday) | 16.88M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.14 |
| 50-Day MA | $3.00 |
| 200-Day MA | $4.15 |
Evaxion Biotech A/S - ADR Stock, NASDAQ:EVAX
Dr. Neergaards Vej 5F, 1260 Copenhagen K, Hoersholm, North Denmark 2970
Denmark
Phone: +45.53.53.18.50
Number of Employees: 49
Description
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen MÃ?Â?ller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.